(Bloomberg) -- WuXi AppTec Co. posted better-than-expected third ... bringing the year-to-date decline to 17%. “Insufficient ...

“In line with growing customer demand, we have also begun looking to identify additional U.S. locations where we can continue to invest in new WuXi AppTec facilities for drug discovery ...

WuXi AppTec, the Shanghai-based biotech giant, has sold its South Philly-based WuXi Advanced Therapies contract manufacturing unit to New York-based Altaris LLC, easing worries that federal limits ...

Shanghai-based WuXi AppTec focuses on drug discovery, development, and manufacturing. Founded in 2001 as WuXi PharmaTech, the company rebranded to its current name after acquiring the U.S.-based ...

Chen told the conference that WuXi Apptec plans to continue expanding small molecule Phase III and commercial pipeline capabilities through 2025 and beyond. Six out of 31 total new small molecules ...

WuXi AppTec’s shares closed up almost 12 per cent to HK$67.10 on Friday, while shares of subsidiary WuXi Biologics rose nearly 15 per cent to HK$21.45. Those gains were made after Financial ...

SHANGHAI, Jan. 12, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides ... supporting our customers in delivering innovative new therapies to patients, working together towards ...